TO
Theriva Biologics, Inc.
TOVX · AMEX
$0.24 +1.41% (+$0.00)
1M -1.83%
Market Cap $10.9M
P/E Ratio -
Div. Yield -
ROE 93.49%
Bulios Fair Price
$0.13
45.1% downside
Current Price
$0.24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TOVX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
50 /100
Fair P/S 36.22x
P/B 0.89x
P/E N/A
Growth
0 /100
Declining Book val. growth 34.43%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 92.00%
Net margin 3,872.67%
Op. margin 3,966.00%
Quality
0 /100
Poor ROIC 51.05%
ROE 93.49%
ROA 33.33%
Debt
82 /100
Low Debt/Equity 0.29x
Current ratio 1.13x
Int. coverage N/A
Stability
48 /100
Moderate Beta 1.15x
EPS volatility 39.49%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TOVX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Steven A. Shallcross
Employees
16
Headquarters
Rockville
Upcoming events
17 NOV
Earnings
Upcoming earnings report